Literature DB >> 17189692

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).

Michael P Clark1, Kelly M George, Roger G Bookland, Jack Chen, Steven K Laughlin, Kumar D Thakur, Wenlin Lee, Jan R Davis, Ed J Cabrera, Todd A Brugel, John C VanRens, Matthew J Laufersweiler, Jennifer A Maier, Mark P Sabat, Adam Golebiowski, Vijay Easwaran, Mark E Webster, Biswanath De, George Zhang.   

Abstract

A new class of bicyclic pyrrolopyrimidine-based Janus kinase 3 (JAK-3) inhibitors are described. Many of these inhibitors showed low nanomolar activity against JAK-3.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17189692     DOI： 10.1016/j.bmcl.2006.12.018

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  12 in total

1.  Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.

Authors:  Maninder Kaur; Pankaj Kumar Singh; Manjinder Singh; Renu Bahadur; Om Silakari
Journal:  Mol Divers       Date:  2017-11-14       Impact factor: 2.943

2.  Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach.

Authors:  Haneesh Jasuja; Navriti Chadha; Maninder Kaur; Om Silakari
Journal:  Mol Divers       Date:  2014-01-11       Impact factor: 2.943

3.  Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions.

Authors:  Ji Hoon Lee; Qi Zhang; Sunhwan Jo; Sergio C Chai; Misook Oh; Wonpil Im; Hua Lu; Hyun-Suk Lim
Journal:  J Am Chem Soc       Date:  2011-02-02       Impact factor: 15.419

4.  Ferrocenes as potential chemotherapeutic drugs: synthesis, cytotoxic activity, reactive oxygen species production and micronucleus assay.

Authors:  Wanda I Pérez; Yarelys Soto; Carmen Ortíz; Jaime Matta; Enrique Meléndez
Journal:  Bioorg Med Chem       Date:  2014-12-19       Impact factor: 3.641

5.  Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.

Authors:  Eric R Goedken; Maria A Argiriadi; David L Banach; Bryan A Fiamengo; Sage E Foley; Kristine E Frank; Jonathan S George; Christopher M Harris; Adrian D Hobson; David C Ihle; Douglas Marcotte; Philip J Merta; Mark E Michalak; Sara E Murdock; Medha J Tomlinson; Jeffrey W Voss
Journal:  J Biol Chem       Date:  2014-12-31       Impact factor: 5.157

6.  New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.

Authors:  Ranjan Behera; Sarah M Thomas; Kojo Mensa-Wilmot
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  Crystal structure of bis-[4-(1H-pyrrol-1-yl)phen-yl] ferrocene-1,1'-di-carboxyl-ate: a potential chemotherapeutic drug.

Authors:  Wanda I Pérez; Arnold L Rheingold; Enrique Meléndez
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-22

Review 8.  Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.

Authors:  Claude Haan; Iris Behrmann; Serge Haan
Journal:  J Cell Mol Med       Date:  2010-01-28       Impact factor: 5.310

9.  Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.

Authors:  Shripad S Bhagwat
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

10.  4-(Pyrimidin-2-yl)piperazin-1-ium (E)-3-carb-oxy-prop-2-enoate.

Authors:  Thammarse S Yamuna; Manpreet Kaur; Jerry P Jasinski; H S Yathirajan
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.